Global Nuclear Medicine/ RadioPharmaceuticals Market size was valued at USD 8,016.1 Million in 2025 and is expected to reach USD 15,895.1 Million by 2034, at a CAGR of 7.90% during the forecast period 2025 – 2034.
Nuclear Medicine/ Radio Pharmaceuticals Market Overview
Nuclear medicine/radiopharmaceuticals is a medical specialty using radioactive tracers to assess bodily functions to diagnose and treat disease. These specially designed radioisotopes are used in the diagnosis of nuclear medicines. It can be attached to several specific molecules, allowing the diagnosis of many diseases, including certain types of cancers.
Various factors, such as new product launches in nuclear medicine/radiopharmaceuticals, increasing incidences and prevalence of the target conditions, increasing adoption of nuclear medicine in the various end-use applications, increasing number of cancer patients, and growing number of technological advancements in the SPECT & PET technologies, are mainly driving the market growth of nuclear medicine/radiopharmaceuticals during the forecast period.
However, factors such as the high cost of nuclear medicine, supply chain disturbances, and less adoption of nuclear medicine in many developing countries are mainly restraining the market growth.
The increasing technological advancements in SPECT and PET technologies are expected to create lucrative opportunities for the market during the forecast period. New product launches in nuclear medicine/radiopharmaceuticals are expected to create lucrative opportunities for market growth during the forecast period.
The key players operating in the market are collaborating with the various end users to develop customized nuclear medicine/radiopharmaceuticals. Thus, the aforementioned factors are expected to create lucrative opportunities for the market during the forecast period.
Report Scope
| Feature of the Report | Details |
| Market Size in 2025 | USD 8,016.1 |
| Projected Market Size in 2034 | USD 15,895.1 |
| Market Size in 2024 | USD 7,429.2 Million |
| CAGR Growth Rate | 7.90% CAGR |
| Base Year | 2024 |
| Forecast Period | 2025-2034 |
| Key Segment | By Type, Modality, Application, End User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
CMI has comprehensively analyzed Global Nuclear Medicine/ RadioPharmaceuticals market. The drivers, restraints, challenges, opportunities, key trends have been explained in depth to depict in depth the scenario of Nuclear Medicine/ Radio Pharmaceuticals market. Segment wise market size and market share for Nuclear Medicine/ Radio Pharmaceuticals during the forecast period is duly addressed to portray the probable picture of the Global Nuclear Medicine/ Radio Pharmaceuticals industry.
The competitive landscape includes key innovators, market giants as well as niche players are studied and analyzed extensively with respect to their strengths, weaknesses as well as value addition prospects. In addition, the report covers Nuclear Medicine/ Radio Pharmaceuticals key players profiling, market shares, mergers and acquisitions, consequent market fragmentation, new trends and dynamics in partnerships.
List of the prominent players in the Nuclear Medicine/ Radio Pharmaceuticals Market:
- GE Healthcare
- The Australian Nuclear Science and Technology Organization
- Eckert and Ziegler
- The Institute for Radioelements
- Eczacibasi-Monrol
- Nordion Inc.
- Bracco Imaging S.P.A
- NTP Radioisotopes SOC Ltd.
- Lantheus Medical Imaging Inc.
- Jubilant Life Sciences Ltd
- Others
The Nuclear Medicine/ Radio Pharmaceuticals Market is segmented as follows:
By Type
- Diagnostics
- Therapeutics
- Biochemistry Research
By Modality
- SPECT
- PET
- Alpha-emitters
- Beta-emitters
- Brachytherapy
By Application
- Oncology
- Urology
- Cardiology
- Neurology
- Thyroid
- Others
By End User
- Hospitals and Diagnostic Centers
- Research Institutes
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America